



Minimum prices of generic Hepatitis C Direct Acting Antivirals fall below US \$50 per person cured

Hill, Andrew¹; Hughes, Sophie²; Simmons, Bryony²; Cooke, Graham²; Khwairakpam, Giten³

¹Liverpool University, Translational Medicine, Liverpool, United Kingdom ²Imperial College London, School of Public Health, London, United Kingdom ³AmFAR/Treat Asia Bangkok Thailand



Correspondence to: Dr Andrew Hill PhD Department of Translational Medicine, 1st Floor Block H, 70 Pembroke Place, Liverpool, L69 3GF Tel:+44 7834 364 608 Email: microhaart@aol.com

Background: Worldwide in 2016, there were 1.6 million people cured of Hepatitis C (HCV) using Direct Acting Antivirals (DAAs), but 1.5 million new HCV infections. Elimination of HCV will only be possible by 2030 if at least 5 million people are cured each year. The World Health Organization has pre-qualified 3 generic forms of DCV. Using data on exports of raw materials in 2015-18, we calculated currently feasible generic prices of HCV DAAs, and compared to current national prices.

Methods: Data on per-kilogram prices of sofosbuvir (SOF), daclatasvir (DCV), ledipasvir (LDV) and velpatasvir (VEL) active pharmaceutical ingredients (API) exported from India were extracted from an online database (www.datamyne.com). All costs were calculated in US dollars (\$). To calculate the cost of the amount of API needed for a 12-week treatment course, we added cost estimates for formulation (\$0.01 per tablet), packaging (US\$0.35/month), and a profit margin of 26%. National prices were extracted from online price databases.

Results: The cost of exported SOF API has fallen from \$10,100/kg in January 2018. Costs of API are currently \$750/kg for DCV, \$2250 for LDV and \$9046 for VEL. The predicted minimum production price for SOF/DCV is now \$48 per 12-week treatment course. Five generic DCV have shown bioequivalence with originator drugs, by FDA criteria. As shown in Table 1, prices of generic SOF/DCV for public tenders in India are close to predicted minimum costs of production. Prices for sale to individuals in India are higher (Table 1). Prices of SOF/DCV in Egypt, Pakistan and Iran are also under \$100 per 12-week course. By contrast, in high income countries, costs per 12-week course are approximately \$8000 to \$20,000, including discounts. Global sales of DAAs worldwide now total over \$77 billion since launch.

The costs of generic production of HCV DAAs are falling rapidly. **Conclusions:**

> SOF/DCV combination treatment can now be produced for US\$48 per patient per 12-week course. SOF/DCV is already on sale in India for \$69 per cure. At these low prices, elimination of HCV worldwide could be feasible. Countries need to demand lower prices for HCV DAAs, to make elimination strategies affordable.

> > Cost of DCV Active

(API) = \$750/kg

Pharmaceutical Ingredient



Cost per cure, SOF/DCV: \$48

Cost of SOF Active

(API) = \$981/kg


Pharmaceutical Ingredient

AASLD

WHO approved generic HCV DAAs

WHO pre-qualified:


Sofosbuvir – Mylan, Hetero and Cipla



exports of API from India to other countries, with costs of API, for many drugs

1 kg sotosbuvir = 5981 (30 patients)1kg daclatasvir = \$750 (190 patients)


PAASLD





PAASLD

Changes in cost/kg of SOF API




Gilead selling generic DAAs in USA PAASLD

Press Release: Gilead Subsidiary to Launch Authorized Generics of Epclusa® (Sofosbuvir/Velpatasvir) and Harvoni®

(Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C (September 24th 2018)

Price of generic SOF/LDV in USA: \$24,000 / cure Cost of generic production: \$68 / cure


http://www.gilead.com/news/press-releases/2018/9/gilead-subsidiary-to-launch-authorized-genericsof-epclusa-sofosbuvirvelpatasvir-and-harvoni-ledipasvirsofosbuvir-for-the-treatment-of-chronichepatitis-c



SOF/DCV can now be produced for <\$50 per 12-week treatment course.

The real cost of HCV elimination

At \$50 per course, it would cost \$3.5 billion to treat all 69 million people infected with HCV worldwide



Therefore, all 69 million people with HCV worldwide could be treated for the equivalent of 4 months of commercial sales of the HCV DAAs

Harvoni 90 mg/400 mg

pasvin/Sofosbu

Zen Einnehmen 26 Filmtabletten 19 GILEAD

2017 AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES WWW AASLD ORG.

Presented at HIV Glasgow, 28th-31st October 2018. Poster number O323.